GC012F

Phase 2Cell therapy

GGracell Biotechnologies (Shanghai) Co., Ltd.

GC012F is one of 126 biologic programs targeting AL amyloidosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

125

Competitors

Pipeline

Status by Indication[3][1]

Indication

AL AmyloidosisRecruiting

Autoimmune DiseaseNot yet recruiting

Multiple MyelomaRecruiting

Myasthenia GravisRecruiting

Relapsed/refractory Multiple MyelomaRecruiting

Refractory Systemic Lupus ErythematosusActive, not recruiting

Idiopathic Inflammatory MyopathyRecruiting

AL AmyloidosisPhase 1

Recruiting

Autoimmune DiseasePhase 1

Not yet recruiting

Multiple MyelomaPhase 2

Recruiting

Myasthenia GravisPhase 1

Recruiting

Relapsed/refractory Multiple MyelomaPreclinical

Recruiting

Refractory Systemic Lupus ErythematosusPreclinical

Active, not recruiting

Idiopathic Inflammatory MyopathyPhase 1

Recruiting

Competition

Competitive Landscape

259 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

47 2

TALVEY

Johnson & Johnson

Phase 3

22 3

Keytruda

Merck & Co.

Phase 3

17 4

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

42 5

Biaxin

AbbVie

Phase 3

14 6

Azatiq

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

22 7

Neulasta

Amgen

Phase 3

5 8

Vepesid

AAvyxa

Phase 3

17 9

Elranatamab

Cytosar

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalActive, not recruiting

Refractory Systemic Lupus Erythematosus

NCT06530849

Q3 2027

Phase 1Recruiting

Myasthenia Gravis

NCT07058298

Phase 1Not yet recruiting

Myasthenia Gravis

NCT06759948

Q4 2028

Phase 1Recruiting

AL Amyloidosis

NCT07250269

Q1 2029

PreclinicalRecruiting

Relapsed/refractory Multiple Myeloma

NCT05850234

Phase 1Not yet recruiting

Autoimmune Disease

NCT07072884

Clinical

Trials by Indication[1]

Multiple Myeloma4 trials

BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma

Unknown status·SShanghai Changzheng Hospital·Phase 1·NCT04617704·15 enrolled

Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma

Unknown status·SShanghai Changzheng Hospital·Phase 1·NCT05412329·9 enrolled

A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting·GGracell Biotechnologies (Shanghai) Co., Ltd.·Phase 1/2·NCT06235229·110 enrolled

Show 1 more trial

BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma

Unknown status·SShanghai Changzheng Hospital·Phase 1·NCT04236011·15 enrolled

Myasthenia Gravis2 trials

GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)

Recruiting·DDaishi Tian·Phase 1·NCT07058298·6 enrolled

An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis

Not yet recruiting·CChongbo Zhao·Phase 1·NCT06759948·18 enrolled

Systemic Lupus Erythematosus2 trials

Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus

Unknown status·ZZhejiang University·Phase 1·NCT05846347·15 enrolled

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

Unknown status·RRenJi Hospital·Phase 1·NCT05858684·18 enrolled

Idiopathic Inflammatory Myopathy1 trial

GC012F Injection in Refractory Idiopathic Inflammatory Myopathy

Recruiting·DDaishi Tian·Phase 1·NCT07086404·12 enrolled

Refractory1 trial

An Exploratory Clinical Study of GC012F Injection for Refractory gMG

Withdrawn·ZZhejiang University·Phase 1·NCT06419166

6 more indications

High Risk1 trial

Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients

Unknown status·SShanghai Changzheng Hospital·Phase 1/2·NCT04935580·20 enrolled

CAR-T1 trial

Study of FasT CAR-T GC012F Injection NDMM Patients

Unknown status·SShanghai Changzheng Hospital·Phase 1·NCT05840107·18 enrolled

Autoimmune Disease1 trial

GC012F in Patients With Autoimmune Diseases

Not yet recruiting·QQiong Fu·Phase 1·NCT07072884·15 enrolled

Relapsed/Refractory Multiple Myeloma1 trial

A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma (DURGA-1)

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT05850234·232 enrolled

Refractory Systemic Lupus Erythematosus1 trial

A Phase 1/2 Clinical Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus

Active, not recruiting·GGracell Biotechnologies (Shanghai) Co., Ltd.·Preclinical·NCT06530849·20 enrolled

AL amyloidosis1 trial

A Phase 1b Study of GC012F, a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B-cell Maturation Antigen in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Recruiting·GGracell Biotechnologies (Shanghai) Co., Ltd.·Phase 1·NCT07250269·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for GC012F. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GC012F compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GC012F. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gracell Biotechnologies (Shanghai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: GGracell Biotechnologies (Shanghai) Co., Ltd.

GC012F

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Q4 2028

Q1 2029

Trials by Indication[1]

Multiple Myeloma4 trials

Myasthenia Gravis2 trials

Systemic Lupus Erythematosus2 trials

Idiopathic Inflammatory Myopathy1 trial

Refractory1 trial

High Risk1 trial

CAR-T1 trial

Autoimmune Disease1 trial

Relapsed/Refractory Multiple Myeloma1 trial

Refractory Systemic Lupus Erythematosus1 trial

AL amyloidosis1 trial

References

Drug Info

Quick Facts

Related News